Insufficient Sleep and Risk of Prostate Cancer in a Large Swedish Cohort
- PMID: 26118562
- PMCID: PMC4531408
- DOI: 10.5665/sleep.4978
Insufficient Sleep and Risk of Prostate Cancer in a Large Swedish Cohort
Abstract
Study objective: There are some data to suggest that insufficient sleep, including short sleep duration and sleep disruption, may be associated with an increased risk of cancer. We investigated the association between sleep duration and sleep disruption and risk of prostate cancer.
Design: Prospective cohort study.
Setting: Sweden.
Participants: A total of 14,041 men in the Swedish National March Cohort.
Interventions: None.
Measurements and results: Habitual sleep duration and sleep disruption were self-reported in 1997. Prostate cancer diagnoses, including lethal (metastases at diagnosis or death from prostate cancer) and advanced (stage T4, N1, or M1 at diagnosis or death from prostate cancer), were determined from linkage to nationwide cancer registries through 2010. We conducted Cox proportional hazards regression adjusted for potential confounding variables. During 13 years of follow-up, we identified 785 cases of incident prostate cancer, including 118 lethal and 127 advanced cases. Four percent of men reported sleeping 5 h or less a night, and 2% reported sleeping 9 h or more per night. We found no association between sleep duration and risk of prostate cancer overall or for advanced/lethal disease. We also did not find an association between prostate cancer and sleep disruption, as defined by difficulty falling asleep, difficulty maintaining sleep, sleep quality, and restorative power of sleep.
Conclusions: In this large prospective study from Sweden, we found no association between habitual sleep duration or sleep disruption and risk of prostate cancer.
Keywords: prostate cancer; sleep disruption; sleep duration.
© 2015 Associated Professional Sleep Societies, LLC.
Figures

Similar articles
-
Sleep Duration and Disruption and Prostate Cancer Risk: a 23-Year Prospective Study.Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):302-8. doi: 10.1158/1055-9965.EPI-14-1274. Epub 2015 Dec 16. Cancer Epidemiol Biomarkers Prev. 2016. PMID: 26677208 Free PMC article.
-
Work schedule, sleep duration, insomnia, and risk of fatal prostate cancer.Am J Prev Med. 2014 Mar;46(3 Suppl 1):S26-33. doi: 10.1016/j.amepre.2013.10.033. Am J Prev Med. 2014. PMID: 24512928
-
Sleep characteristics and cardiovascular events in a large Swedish cohort.Eur J Epidemiol. 2013 Jun;28(6):463-73. doi: 10.1007/s10654-013-9802-2. Epub 2013 Apr 4. Eur J Epidemiol. 2013. PMID: 23553209
-
Familial prostate cancer in Sweden. A nationwide register cohort study.Cancer. 1996 Jan 1;77(1):138-43. doi: 10.1002/(SICI)1097-0142(19960101)77:1<138::AID-CNCR23>3.0.CO;2-5. Cancer. 1996. PMID: 8630920 Review.
-
Sleep disorders and prostate cancer prognosis: biology, epidemiology, and association with cancer development risk.Eur J Cancer Prev. 2022 Mar 1;31(2):178-189. doi: 10.1097/CEJ.0000000000000685. Eur J Cancer Prev. 2022. PMID: 33990093 Review.
Cited by
-
Sleep disruption, chronotype, shift work, and prostate cancer risk and mortality: a 30-year prospective cohort study of Finnish twins.Cancer Causes Control. 2016 Nov;27(11):1361-1370. doi: 10.1007/s10552-016-0815-5. Epub 2016 Oct 12. Cancer Causes Control. 2016. PMID: 27734240 Free PMC article.
-
The association between sleep duration and prostate cancer: A systematic review and meta-analysis.Medicine (Baltimore). 2020 Jul 10;99(28):e21180. doi: 10.1097/MD.0000000000021180. Medicine (Baltimore). 2020. PMID: 32664160 Free PMC article.
-
The Global Problem of Insufficient Sleep and Its Serious Public Health Implications.Healthcare (Basel). 2018 Dec 20;7(1):1. doi: 10.3390/healthcare7010001. Healthcare (Basel). 2018. PMID: 30577441 Free PMC article. Review.
-
Actigraphy-derived measures of sleep and risk of prostate cancer in the UK Biobank.J Natl Cancer Inst. 2024 Mar 7;116(3):434-444. doi: 10.1093/jnci/djad210. J Natl Cancer Inst. 2024. PMID: 38013591 Free PMC article.
-
Circadian pathway genetic variation and cancer risk: evidence from genome-wide association studies.BMC Med. 2018 Feb 19;16(1):20. doi: 10.1186/s12916-018-1010-1. BMC Med. 2018. PMID: 29455641 Free PMC article.
References
-
- Davis S, Mirick DK. Circadian disruption, shift work and the risk of cancer: a summary of the evidence and studies in Seattle. Cancer Causes Control. 2006;17:539–45. - PubMed
-
- Blask DE. Melatonin, sleep disturbance and cancer risk. Sleep Med Rev. 2009;13:257–64. - PubMed
-
- Costa G, Haus E, Stevens R. Shift work and cancer - considerations on rationale, mechanisms, and epidemiology. Scand J Work Environ Health. 2010;36:163–79. - PubMed
-
- Reiter RJ. Melatonin: clinical relevance. Best Pract Res Clin Endocrinol Metab. 2003;17:273–85. - PubMed
-
- Sainz RM, Mayo JC, Tan DX, León J, Manchester L, Reiter RJ. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate. 2005;63:29–43. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical